Impact of Lamivudine plus Adefovir therapy in chronic hepatitis B Iranian patients, resistant to Lamivudine treatment alone, on disease inhibition: A pilot study

Arezoo Estakhri, Ashraf Mohamadkhani, Hosein Poustchi, Ghodrat Montazeri

Digestive Disease Research Institute (DDRI), Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Email: arezooestakhri@yahoo.com

Received 12 December 2011; revised 16 February 2012; accepted 18 February 2012

ABSTRACT

AIM: To evaluate the impact of combination therapy with Lamivudine and Adefovir for treatment of chronic hepatitis B in Lamivudine-resistant patients. METHODS: Among the 110 adult chronic hepatitis B Iranian patients whom were treated with Lamivudine, for 36 months, nineteen patients (17%) with no any biochemical and viral responses to Lamivudine alone, were selected and enrolled in the study. Due to resistancy, Adefovir was added to Lamivudine, and continued for 30 months. We measured HBV_DNA viral load and serum AST, ALT in 0, 12, 24, 30 and 0, 6, 12, 18, 24, 30 months, respectively. RESULTS: Between biochemical and viral characteristics, Repeated Measure analysis identified just biochemical markers—Aspartate Aminotransferase level (AST) (P = 0.002) and Alanine Aminotransferase level (ALT) (P = 0.007) —as predictors of response to treatment, while, viral marker—HBV DNA load—was not statistically significant (P = 0.128). CONCLUSIONS: Treatment for a long time, such as 21.5 ± 8.8 months, with Lamivudine and Adefovir, can cause liver enzymes including AST and ALT, decreasing and being normal. But, this finding is not indicative, for HBV-DNA viral load.

Keywords: Adefovir Dipivoxil; Lamivudine-Resistant; Chronic Hepatitis B; Combination Treatment

1. INTRODUCTION

Chronic hepatitis B is one of the main causes of liver damage such as liver cirrhosis and hepatocellular carcinoma [1]. But, these events can be prevented by appropriate therapy. There are five approved (1998-2008) nucleos(t)ide analogues, for hepatitis B treatment. One of them, which is very common and has been used as the first line therapy for several years, is Lamivudine. The main problem with this drug is increasing resistancy more than 65% in five years treatment [2]. Another important issue, is lower potency of using antiviral drugs, separately, compared with administration together. Studies show that adding the second drug like Adefovir, to Lamivudine, can lead to desired results [3]. In order to evaluate the efficacy of Lamivudine plus Adefovir therapy with regards to prevent long-term mentioned harms of disease, in patients with resistancy to Lamivudine alone, we performed this study.

2. PATIENTS AND METHODS

2.1. Patients

From March 2006 to March 2009, a total of 110 adult patients with chronic hepatitis B were treated with Lamivudine in our outpatient clinic. Among them, nineteen patients (17%) developed resistance (YMDD mutant) and were enrolled in the study. YMDD mutation, was confirmed by Direct Sequencing. Then, Adefovir was added to Lamivudine. Treatment with two drugs lasted, 21.5 ± 8.8 months. Inclusion criteria for selecting patients and no response to Lamivudine alone, were: 1) Liver enzymes specially ALT, more than 60 IU/L after a period of being in normal range (at least: 2.5 years); 2) High level of HBV-DNA [more than 10^5 copies/mL] in 2 times checking (at least: 6 months) after a period of being in normal range.

2.2. Methods

At first, all of 110 patients received Lamivudine alone with a dose of 100 mg/daily for 3 years. Among them, patients with resistance to the first drug, were selected and treated with two drugs, Lamivudine and Adefovir (10 mg/daily) for 30 months. Liver function tests, including AST and ALT, were measured every 6 months after adding the second drug. Moreover, HBV-DNA viral load was assessed each 12 months, for 36 months, by Real Time PCR assay (Taqman). All patients provided
written informed consent before therapy was given.

2.3. Statistical Analysis
We recorded and analyzed our data by using SPSS (version 16, Inc, Chicago, IL). Repeated measure test was used to evaluate the changes of both, biochemical and virological markers, during 36 months of combination treatment.

A P value of less than 0.05 was considered to be statistically significant.

3. RESULTS

3.1. Baseline Characteristics of Patients
The baseline characteristics of the patients are shown in Table 1.

3.2. Changes of AST, ALT and HBV-DNA Levels by Two Drugs Treatment
As in Table 2, serum AST and ALT levels were normalized after 30 months treatment with Lamivudine and Adefovir (Figures 1 and 2). While, there is no any good changes in serum HBV-DNA levels. This means that, the level of serum HBV-DNA has been low in 12 and 30 months, while it has been high in 24 months of combination treatment (Figure 3).

4. DISCUSSION
There are several studies about combination treatment with Lamivudine and Adefovir in chronic hepatitis B [4], HBeAg negative patients, resistance to Lamivudine

Table 1. Baseline characteristics of patients.

| Age (yr) | 44.7 ± 8.1 |
| Male | 68.4% |
| Female | 31.6% |
| Duration of combination treatment (months) | 30.2 ± 5.3 |
| Baseline ALT | 188.4 ± 224.0 |
| Baseline HBV-DNA (log10 copy/ml) | 1.98E7 ± 5.75E7 |

Table 2. Changes of mean serum ALT, AST and HBV-DNA levels during combination treatment.

<table>
<thead>
<tr>
<th>Months after adding Adefovir</th>
<th>0</th>
<th>6</th>
<th>12</th>
<th>18</th>
<th>24</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-Value (ALT)</td>
<td>188.4 ± 224.0</td>
<td>114.1 ± 107.1</td>
<td>1.98E7 ± 5.7E7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>41.4 ± 30.2</td>
<td>31.8 ± 11.4</td>
<td>5.5E4 ± 209144.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>33.4 ± 24.9</td>
<td>24.5 ± 8.6</td>
<td>3.15E6 ± 1.37E7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>28.2 ± 16.9</td>
<td>24.5 ± 7.7</td>
<td>1.25E4 ± 53891.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>24 ± 10.9</td>
<td>23.7 ± 5.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>22.2 ± 5.3</td>
<td>22.2 ± 5.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
</tbody>
</table>

(HBV-DNA log10 copies/ml)
alone. Also, it has been shown that the rate of resistance in treatment with Adefovir is lower than Lamivudine [5]. On the other hand, there is no any robust consensus about long-term combination treatment in patients with resistance to Lamivudine, alone [6]. So, we evaluated 19 patients with mentioned criteria, to assess the efficacy of 2 drugs long-term treatment [30 months].

There are several studies about short-term treatment with Lamivudine and Adefovir. Lui et al. [7] showed that 2 drugs treatment, for more than two months has better only virological response. Also, Akyildiz et al. [8] found that there was no any difference in virological and biochemical responses with and without adding Adefovir to Lamivudine for three months.

In another study, Rapti et al. [9] showed that, resistance to Adefovir is less frequent, in combination therapy.

On the other hand, in another research, it was concluded that treatment with Adefovir plus Lamivudine is more effective in patients, with Lamivudine-resistant chronic hepatitis B [10]. Moreover, Buti M et al. [11] and Lampertico P et al. [12] in different studies found that, there are some factors like serum AST and HBV-DNA levels, that predict virological and biochemical responses in combination therapy. However, in another two studies, it has been shown that Tenofovir is efficient for patients with Lamivudine-Adefovir resistant [13,14]. But, it needs more studies with a longer time.

On the other hand, some studies show that, adding Adefovir to Lamivudine in early stages of resistance, is better than adding it, when, resistance has been occurred for a long time [15].

Moreover, earlier studies have established that Adefovir is extremely effective in cases with Lamivudine-resistance during 60 weeks of treatment [16].

Our study, includes small population, but gives the information about the response to long-term combination therapy, with Lamivudine and Adefovir in genotype D—Iranian patients, resistant to Lamivudine alone. These patients, showed biochemical response—decreasing serum AST and ALT levels (Figures 1 and 2)—however, incomplete response for decreasing of serum HBV-DNA viral load. In other words, viral load has had fluctuation, not constant decreasing level in serial months (Figure 3).

In conclusion, during long time such as 30 months, treatment with ADF and Lamivudine make liver enzymes—serum AST and ALT—being in normal range, yet virological response is incomplete.

REFERENCES

level during Adefovir therapy. *Hepatology, 44*, 318-325. doi:10.1002/hep.21253
